Immunotherapeutic studies of head and neck tumors: Highlights of the 2016 ASCO Annual Meeting;Immuntherapeutische Studien bei Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016

HNO

Volumn 64, Issue 10, 2016, Pages 708-716

  Busch, C J ^a   Laban, S ^b   Knecht, R ^a   Hoffmann, T K ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

CTLA 4 antigen; Immunomodulation; Nivolumab; PD 1 receptor; Squamous cell carcinoma of the head and neck

Indexed keywords

CANCER VACCINE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

CARCINOMA, SQUAMOUS CELL; EVIDENCE BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; TRENDS;

ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; EVIDENCE-BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84986281485     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-016-0238-3     Document Type: Article

References (18)

1. Bauml J, Seiwert TY, Pfister DG et al (2016) Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). ASCO Meet Abstr 34:6011
2. Cohen EEW, J‑PH M, Harrington KJ et al (2015) KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. ASCO Meet Abstr 33:TPS6084
3. Cohen RB, Delord J‑P, Doi T et al (2016) Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. ASCO Meet Abstr 34:6017
4. Ferris RL, Blumenschein GR, Fayette J et al (2016) Further evaluations of nivolumab (nivo) versus investigators choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. ASCO Meet Abstr 34:6009
5. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028
6. Hodi FS, O’Day SJ, Mcdermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
7. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34
8. Mehnert JM, Varga A, Brose M et al (2016) Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. ASCO Meet Abstr 34:6091
9. Mehra R, Seiwert TY, Mahipal A et al (2016) Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012. ASCO Meet Abstr 34:6012
10. Powell SF, Liu SV, Sukari A et al (2015) KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab. ASCO Meet Abstr 33:TPS3094
11. Powell SF, Gitau MM, Spanos WC et al (2016) Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN). ASCO Meet Abstr 34:TPS6107
12. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
13. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532
14. Seiwert TY, Haddad RI, Gupta S et al (2015) Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. ASCO Meet Abstr 33:LBA6008
15. Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. doi:10.1016/s1470-2045(16)30066-3
16. Seiwert TY, Weiss J, Baxi SS et al (2016) A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) {+/-} tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL. ASCO Meet Abstr 34:TPS6101
17. Uppaluri R, Zolkind P, Lin T et al (2016) Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma. ASCO Meet Abstr 34:TPS6110
18. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133